Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 24, Issue 4, Pages (December 2017)

Similar presentations


Presentation on theme: "Volume 24, Issue 4, Pages (December 2017)"— Presentation transcript:

1 Volume 24, Issue 4, Pages 281-290 (December 2017)
The Garcinia kola biflavonoid kolaviron attenuates experimental hepatotoxicity induced by diclofenac  Quadri Kunle Alabi, Rufus Ojo Akomolafe, Olaoluwa Sesan Olukiran, Wale Johnson Adeyemi, Aliyat Olajumoke Nafiu, Modinat Adebukola Adefisayo, Joseph Gbenga Omole, Deborah Ifeoluwa Kajewole, Oluwole Olaniyi Odujoko  Pathophysiology  Volume 24, Issue 4, Pages (December 2017) DOI: /j.pathophys Copyright © 2017 Elsevier B.V. Terms and Conditions

2 Fig. 1 Chemical structures of the bioactive compounds present in kolaviron. Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions

3 Fig. 2 Scheme illustration of extraction process of kolaviron.
Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions

4 Fig. 3 Effects of kolaviron and Livolin forte® on Tumour Necrosis Factor Alpha (TNF-α) Levels in Rats Treated with DCLF. Each value represents mean±SEM (n=5). *=significantly different from control. α=significantly different from group 2. ω=significantly different from groups 3,4 and 5 (p<0.05). Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions

5 Fig. 4 Effects of Kolaviron and Livolin forte® on Interleukin-1 (IL-1β) levels in Rats Treated with DCLF. Each value represents mean±SEM (n=5). *=significantly different from control. α=significantly different from group 2. ω=significantly different from groups 3,4 and 5 (p<0.05). Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions

6 Fig. 5 Histological scores for hepatotoxicity. (A) Control group with normal architecture (0). (H&E, ×400); (B) Group 2 (DCLF alone). Showing dilated central vein, mild paracentral, hepatocyte cell loss, prominent cell death and inflammation in the centrilobular areas (+3). (H&E, ×400); (C) DCLF and LIV group. Few centrilobular cell death and minimal inflammation. (H&E, ×400); (D) DCLF and 100mg/kg KV group. Mild cell death and minimal inflammation in the centrilobular areas (+1). (H&E, ×400); (E) DCLF and 200mg/kg KV group. A few cell deaths in the centrilobular areas. (H&E, ×400); (F) DCLF and 400mg/kg KV. Sinusoidal congestion, kupffer cell hyperplasia, cell death and inflammation in the centrilobular areas (+3). The black arrow shows cellular infiltration by mononuclear cells. The red arrow shows the lymphocyte cells. The yellow arrow shows the cell death. Haematoxylin and eosin (H & E) stain at ×400 magnification. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions

7 Fig. 6 Histological scores for hepatotoxicity. (A) Control group with normal architecture. (H&E, ×400); (B) Group 2 (DCLF recovery). Showing minimal hepatocyte cell loss, moderate cell death and inflammation in the centrilobular areas (+2) (H&E, ×400); (C) Group 3 (DCLF and LIV recovery group). Few centrilobular cell death and no inflammation. (H&E, ×400); (D) Group 4 (DCLF and 100mg/kg KV recovery group). Mild cell death and no inflammation in the centrilobular areas (+1). (H&E, ×400); (E) Group 5 (DCLF and 200mg/kg KV recovery group). A few cell deaths in the centrilobular areas. (H&E, ×400); (F) Group 6 (DCLF and 400mg/kg KV recovery group). Mild kupffer hyperplasia, moderate cell death and inflammation in the centrilobular areas (+2). (H&E, ×400). The black arrow shows cellular infiltration by mononuclear cells. The red arrow shows the lymphocyte cells. The yellow arrow shows the cell death. Haematoxylin and eosin (H & E) stain at ×400 magnification. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Pathophysiology  , DOI: ( /j.pathophys ) Copyright © 2017 Elsevier B.V. Terms and Conditions


Download ppt "Volume 24, Issue 4, Pages (December 2017)"

Similar presentations


Ads by Google